














## 5<sup>th</sup> International Conference

# HUS & related disorders

Current diagnosis and therapy of hemolytic uremic syndrome (HUS), and related disorders





doctoral programme

Congresspark IgIs Innsbruck-Igls, Austria July 12-14, 2015

### **Programme:**

Sunday, July 12

13.00 - 18.30 Lectures and Free Communications

18.00 - 20.30 *Welcome reception* 

Monday, July 13

08.30 - 17.30 Lectures, Free Communication & Posters

19.00 Tyrolean Night

Tuesday, July 14

08.30 - 13.00 Lectures and Free Communications

Congress President: Reinhard.Wuerzner@i-med.ac.at, www.hus-online.at

Deadline for abstracts: June 1st

Registration open: May 1<sup>st</sup> - June 30<sup>th</sup>, 2015

Registration fee: EUR 250,00

Resident in training: EUR 150,00

Students: EUR 50,00

In the registration fee included are all meals, coffee breaks, welcome reception and Monday evening gala dinner.

#### Address of venue:

Congresspark Igls, Eugenpromenade 2, A-6080 Igls, Österreich ★ +43-512-59360

Hotel accommodation (please mention "HUS-Meeting")

Sporthotel Igls \*\*\*\*, Hilberstraße 17, A-6080 Igls ★ +43-512-377-241, http://www.sporthotel-igls.com

Reduced rate for participants:

Single € 98 (including breakfast and all taxes)
Double € 170 (including breakfast and all taxes)

Eagles Astoria Hotel Igls \*\*\*\*, Badhausstraße 1, A-6080 Igls #43-512-377-4810, http://www.eagles.at

Reduced rate for participants:

Single € 85 (including breakfast and all taxes)
Double € 140 (including breakfast and all taxes)

Reduced rate for participants:

Single € 80 (including breakfast and all taxes)
Double € 100 (including breakfast and all taxes)

<u>Nearest airport</u>: Innsbruck Airport (INN) 10 km, but flights are usually much cheaper to/from Munich Airport (MUC) 190 km - from there take a pre-booked (!) Four-Seasons-Taxi https://www.tirol-taxi.at for 70 Euro (return, directly to/from your hotel - mention "HUS" to get the cheap fare).

## Sunday, July 12

10:00 – 18:30		Registration open
12:45		Welcome from Innsbruck Medical University Vice Rector Bandtlow/Würzner
l.		I hemolytic uremic syndrome (aHUS) rs: ZZ, YZ
13:00	L1	aHUS - Role of complement, overview Meri, FI
13:30	L2	aHUS - Role of lectin pathway & coagulation Garred, DK
14:00	L3	aHUS - Spectrum of mutations Roumenina, FR
14:30 – 15:00		Coffee break
15:00	L4	aHUS –Novel insights into pathogenesis <u>Licht, CA</u>
15:30	L5	aHUS – Endothelial cell integrity and complement <u>Riedl, CA</u>
16:00		2 free short communications (FCs)
16:30 – 17:00		Coffee break
II. E. coli associated hemolytic uremic syndrome (eHUS) Chairs: ZZ, YZ		
17:00	L6	SPECIAL LECTURE eHUS & Shiga toxin – the early days Karmali, CA
17:30	L7	Shiga toxin – from gut to kidneys Brigotti, IT
18:00	L8	Shiga toxin effects – evidence from animal studies Obata, JP
18:30		2 FCs
19:00		Welcome reception at the Congresspark Igls

## Monday, July 13

IVIOTIGE	ty, July 13			
III. E. coli associated hemolytic uremic syndrome (eHUS) & complement Chairs: ZZ, YZ				
08:30	L9	Alternative pathway and podocytes <u>Morigi, IT</u>		
09:00	L10	Complement control proteins and coagulation Orth-Höller, AT		
09:30		2 FCs		
10:00 -	- 10:30	Coffee break		
IV.	Other HUS Chairs	S forms : ZZ, Gerhard Gaedicke		
10:30	L11	Post transplant HUS – alloantibodies & endothelial injury M. Stegall, US		
11:00	L12	BMTx associated thrombotic microangiopathy <u>S. Jodele, US</u>		
11:30		4 FCs		
12:30 -	- 13:30	Lunch break		
13:30		Poster Session with desert		
V. Clinical courses of aHUS and related disorders – 4 cases Chairs: N. Van de Kar, NL; XX				
14:30		4 case reports		
15:30 -	- 16:00	Coffee break		
VI. C3 glomerulopathy (C3G) Chairs: ZZ, YZ				
16:00	L13	C3G – consensus report <u>M. Pickering, UK</u>		
16:30	L14	C3G – role of the factor H related family P. Zipfel, DE		
17:00		2 FCs		
19:00		Tyrolean Night at the Sporthotel Igls		

## Tuesday, July 14

VII.	Treatment and monitoring I Chairs: ZZ, YZ		
08:30	L15	Treatment of aHUS with eculizumab - studies <u>C. Bedrosian, US</u>	
09:00	L16	Treatment of aHUS with eculizumab – clinical experiences <u>C. Loirat, FR</u>	
09:30		4 FCs	
10:30 – 11:00		Coffee break	
VIII.	Treatment & monitoring II Chairs: ZZ, YZ		
11:00	L17	Monitoring eculizumab therapy <u>M. Noris, IT</u>	
11:30	L18	Treatment of anti-factor H-associated HUS <u>A. Bagga, IN</u>	
12:00	L19	Treatment targeting the complement alternative pathway <u>C. Harris, UK</u>	

13:00 – 14:00 Farewell and lunch

12:30 2 FCs